SCHEMBL29348198

SCHEMBL29348198

O=C1CCC(c2cccc(-c3ccc(-n4ccccc4=O)cc3)c2Cl)C(=O)N1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 16/20 0.45
CRBN Q96SW2 16/20 0.45
IKZF3 Q9UKT9 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CHRM2 P08172 1/20 0.38
OPRM1 P35372 1/20 0.38
CYP1A2 P05177 1/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
TNF P01375 1/20 0.35
IL1B P01584 1/20 0.35
TBXA2R P21731 1/20 0.35
IKZF1 Q13422 1/20 0.35
F10 P00742 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29348202 1.00 DDB1 (0.45) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL29348199 1.00 DDB1 (0.45) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL31068340 0.89 DDB1 (0.43) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL31068186 0.87 DDB1 (0.51) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL29348466 0.87 DDB1 (0.51) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL29348460 0.87 DDB1 (0.45) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL29348470 0.87 DDB1 (0.42) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL29348798 0.87 DDB1 (0.42) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL31068235 0.86 CNR2 (0.43) DDB1CRBNIKZF3ALDH1A1CHRM2
SCHEMBL31068130 0.86 DDB1 (0.42) DDB1CRBNIKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026013581-A1 DOSAGE FORMS COMPRISING A VAV1 DEGRADER MONTE ROSA THERAPEUTICS AG (CH) 2026-01-15 WO disclosed
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL DDB1 1125/4885CRBN 144/4885IKZF3 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.